HOME >> BIOLOGY >> NEWS
Other highlights in the Jan. 17 JNCI

Calcium Supplements Offer Prolonged Protection Against Colorectal Adenomas in High-Risk Patients

Previous studies have shown that people with noncancerous colorectal tumors called adenomas who take calcium supplements for 4 years can reduce their risk of an adenoma recurrence. A new study shows that the protective effect of those supplements lasts for up to 5 years after stopping supplementation.

In the Calcium Polyp Prevention Study, 930 people with a recent adenoma were randomly assigned to receive 4 years of daily 1200-milligram calcium supplements or a placebo. The study revealed that those assigned to calcium supplements had a 17 percent lower relative risk of an adenoma recurrence than those who got the placebo.

In the new study, Maria V. Grau, M.D., and John A. Baron, M.D., of Dartmouth Medical School, and colleagues followed 822 of the patients from that trial after the end of the treatment. Their aim was to compare the risk of recurrence among participants who had taken calcium with the risk among those who had taken a placebo.

The researchers found that, in the first 5 years after the end of the treatment, people in the calcium group continued to have a lower risk of adenomas than those in the placebo group: 31.5 percent of people who had taken calcium had recurrences compared with 43.2 percent of those originally in the placebo group. However, after 5 years, this protective effect disappeared.

"Our study provides further evidence of the potential of calcium as a chemopreventive agent against colorectal adenomas among individuals with a history of these tumors," the authors write. "Our data indicate that, in these patients, the protective effect of calcium may extend for up to 5 years after the cessation of active treatment."

"Where do we go from here--and, more important, what public health recommendations related to calcium do we provide for risk reduction of colorectal cancer?" ask ed
'"/>

Contact: Andrea Widener
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
16-Jan-2007


Page: 1 2 3 4 5 6 7

Related biology news :

1. Other highlights in the Aug. 7 JNCI
2. Other highlights in the July 24 JNCI
3. Other highlights from the July 10 JNCI
4. Other highlights in JNCI, June 26
5. Other highlights in JNCI, June 12
6. Other highlights from the June 6 JNCI
7. Other highlights in the May 16 JNCI
8. Other highlights from the April 18 Journal of the National Cancer Institute
9. Other highlights from the March 21 JNCI
10. Other highlights in the March 7 JNCI
11. Other highlights in the Feb. 21 JNCI

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/14/2019)... ... 14, 2019 , ... Representatives with MyBioGate announced that China Focus@Biotech Week will ... “We help innovative projects connect with Chinese pharma and investors in healthcare innovation,” said ... to explain that as a part of Biotech Week Boston – the annual biotech ...
(Date:8/14/2019)... ... August 13, 2019 , ... Join Anguraj Sadanandam, ... Institute of Cancer Research (ICR) in a live webinar on Wednesday, ... of biomarker and companion diagnostic development including machine learning approaches in different gastrointestinal ...
(Date:8/9/2019)... ... August 09, 2019 , ... With a demand in ... and more patients will visit urgent care centers (UCC) in the coming years, according ... report, The Market for Urgent Care Centers , is a detailed look at ...
Breaking Biology News(10 mins):
(Date:6/18/2019)... ... June 17, 2019 , ... IVERIC bio, ... an agreement for production and manufacturing of GMP-grade adeno-associated virus (AAV) vector for ... dominant retinitis pigmentosa (RHO-adRP) and IC-200 for the treatment of BEST1 related retinal ...
(Date:6/11/2019)... ... June 10, 2019 , ... ... technology in an upcoming episode, scheduled to broadcast 4Q/2019. Check your local listings ... and will educate viewers about how its technology facilitates laboratories to improve efficiency ...
(Date:6/11/2019)... ... June 11, 2019 , ... A study released ... cells (MSC-EV) are able to incorporate into human CD34+ cells, modifying their gene ... MSC-EVs also increased the cells’ ability to lodge into bone marrow. This research ...
(Date:5/31/2019)... (PRWEB) , ... May 30, 2019 , ... ... regulatory thinking on Data Integrity on July 08-09, 2019 in Boston, MA. This ... biotech and medical device organizations. , The training will kick off with a ...
Breaking Biology Technology:
Cached News: